CENPU

Across TCGA pan-cancer cohorts, CENPU Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CENPU data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CENPU Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CENPU expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, READ, and LUSC are the cancer types where CENPU Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.111	0.730	<.001	33	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	15	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
SKCM	OS	Median	All	0.385	0.790	.001	7	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →
UCEC	DFS	Median	All	1.000	0.635	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CENPU–STAD (OS)

Open the STAD breakdown →